Harbour Antibodies signs agreement with Lilly Agreement aimed at validating a transgenic mouse platform for the generation of human antibodies Harbour Antibodies BV, an Erasmus MC spin-off company announced today the completion of a non-exclusive research and licence agreement with Eli Lilly and Company (“Lilly”), a global pharmaceutical company, to generate and develop human therapeutic antibodies comprising immunoglobulin heavy and light chains (H2L2) using one of Harbour’s transgenic mouse antibody discovery platforms. Under the terms of the agreement Harbour will receive an upfront payment, success-based fees, and potential downstream product milestones and royalties. Specific financial terms were not disclosed. “We are delighted to partner with Lilly,” said Professor Frank Grosveld, …